A plan for mental illness

Thomas R. Insel, Barbara J. Sahakian (), Valerie Voon, Jeffrey Nye, Verity J. Brown, Bruce M. Altevogt, Ed T. Bullmore, Guy M. Goodwin, Robert J. Howard, David J. Kupfer, Gavin Malloch, Hugh M. Marston, David J. Nutt, Trevor W. Robbins, Stephen Stahl, Mark D. Tricklebank and John H. Williams
Additional contact information
Thomas R. Insel: Thomas R. Insel is at the National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
Barbara J. Sahakian: University of Cambridge, Cambridge, UK. bjs1001@cam.ac.uk
Valerie Voon: University of Cambridge, Cambridge, UK.
Jeffrey Nye: Jeffrey Nye is at Janssen Pharmaceutical of Johnson and Johnson, Titusville, New Jersey, USA.
Verity J. Brown: Verity J. Brown is in the School of Psychology, St Andrews University, St Andrews, UK.
Bruce M. Altevogt: Bruce M. Altevogt is at the Institute of Medicine, Forum on Neuroscience and Nervous System Disorders, Washington DC, USA.
Ed T. Bullmore: Ed T. Bullmore is at GlaxoSmithKline, Clinical Unit, Addenbrookes Hospital, Cambridge, UK.
Guy M. Goodwin: University of Oxford, Oxford, UK.
Robert J. Howard: Robert J. Howard is at the Royal College of Psychiatrists and Institute of Psychiatry, King’s College London, London, UK.
David J. Kupfer: David J. Kupfer is in the University of Pittsburgh School of Medicine, Pittsburg, Pennsylvania, USA.
Gavin Malloch: Gavin Malloch is at the Medical Research Council, London, UK.
Hugh M. Marston: Hugh M. Marston is at TPP Global Development, Edinburgh, UK.
David J. Nutt: David J. Nutt is at the Centre for Pharmacology and Therapeutics, Imperial College London, London, UK.
Trevor W. Robbins: University of Cambridge, Cambridge, UK.
Stephen Stahl: Stephen Stahl is in the Behavioural and Clinical Neurosciences Institute, University of Cambridge, Cambridge, UK, University of California, San Diego, San Diego, California, USA.
Mark D. Tricklebank: Mark D. Tricklebank is at Eli Lilly and Co Ltd, Windlesham, UK.
John H. Williams: John H. Williams is at the Wellcome Trust, London, UK.

Nature, 2012, vol. 483, issue 7389, 269-269

Abstract: The Royal Society International Seminar Consortium describes what the next decade of mental-health drug development should look like.

Date: 2012
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/483269a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:483:y:2012:i:7389:d:10.1038_483269a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/483269a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().